It’s the longest life period for retrofitting the end-stage pulmonary pulmonary cancer. Mr. Zhang, Professor Fong
One of the longest life-cycles of end-of-life treatment for small cell lung cancer! Zhang Liang, Professor Fong Feng’s team proposed a new joint drug programme
The study included late-stage small-cell lung cancer patients and provided Sovan with treatment on a line-by-line basis for Ni+Tripli.
The results showed an objective mitigation rate of 97.1 per cent (34/35), a disease control rate (DCR) and a tumor contraction rate of 100 per cent (35/35). In sum, the four drug programmes proposed in this study, “Sofanidini+Tripley One-System + Trapoll+ Shun Peng”, have some advantages in terms of efficacy.
Click to read original
Professor Wu Illong’s team led the 3rd EVEREST study: Zorifertinib is expected to become a new option with CNS moving EGFR mutation NSC!
The first BLOOM study showed that Zorifertinib had a good clinical tumour-resistant activity, and at 200 mg, the total mitigation rate for EGFRm+ NSCLC and for central nervous system transfer patients (ORR) was 67 and 87 per cent, respectively. Two CTONG1702 studies showed 80 per cent of untreated EGRFR m+ NSCLC and Zorifertinib (200mg) treatment for patients with a central nervous system, 15.8 months for the medium PFS and 18.5 months for the medium skull PFS.
The EVEREST test is the first random comparison of efficacy and safety between the first line of Zorifertinib and the first generation of EGFR-TKIs in the later stage of EGFR m+ NSCLC and non-radio-central nervous system transfer. Compared to the first generation of EgFR-TKIs, the first-line treatment of EgFRm+ NSCLC and untreated CNS patients can significantly prolong PFS in whole and inside the skull. In summary, the study supports Zorifertinib ‘ s first-line choice as a new, well-tested treatment of EGFR mutation of NSLC patients.
Click to read original
3. Ia/IB EMBER study: Imlunestrant ‘ s monopharmaceutical and combined target treatment potential in ER+/HER2-ABC treatment
The study included ER+/HER2-ABC patients, using an i3+3-dose incremental design, followed by a dose extension of Imlunestrant or a combination of Abesili (± aromatic enzyme inhibitor [AI]), Iwimos or Aberlis. Imlunestrant gives it in oral form once a day and is given with a combination of drugs according to the relevant label.
The results show that the median PFS for Imlenestrant+Abesili was 19.2 months (95 per cent CI, 13.8 per cent unreachable), while the median PFS for Imlenestrant+Abesili+AI was not achieved. Imlunestrant+Ivimos/Apelies median PFS is 15.9 months (95% CI, 11.3-19.1) and 9.2 months (95% CI, 3.7-11.1). The tumour-resistant activity was demonstrated regardless of the ERS1 mutation. In summary, the study initially confirmed the potential of imlunestrant (400 mg per day oral) to treat ER+/HER2-ABC as a single drug or combination of target treatment.
Click to read original
4. STTT(IF 40.8) | Professor Liantinbo ‘ s team: the Nvory single + gallon + TACE programme has brought high rates of ORR and surgical conversion to uHC patients
The study included mid-term uHCC patients and was treated with the Nvory Monovalence, Lendini and TACE.
The results showed that the objective mitigation rate (ORR) was 50 per cent and the disease control rate (DCR) 83.3 per cent according to the RECIST 1.1 criterion; both the ORR and DCR were as high as 83.3 per cent according to the modified RECIST (mRECIST) standard. The median non-progressive survival period (PFS) was 7.58 months, the median total survival period (OS) was 19.9 months and the annual OS rate was 88.9 per cent. In summary, studies have shown the potential for some efficacy in the treatment of non-extractable liver cell cancer (uHCC) by Envaflimab, Lenvatinib and TACE.
Click to read original
5. Consensus of Chinese experts on palliative care for lung cancer
The consensus proposes that patients with lung cancer should have effective control over the associated symptoms of pain, cough and so forth through early identification and positive assessment, and that active and comprehensive patient-centred medical care should not be conditioned by differences in concepts affecting the delivery of palliative care (1A); and that palliative care should aim at improving the quality of life of patients, their families and caregivers (1A). The E-warm model (1A) is recommended. Patients can begin to receive palliative care at the time of the diagnosis and throughout the treatment process, and those who fail to begin palliative care at an early stage of the disease should continue to be actively involved in the management of subsequent illnesses, such as palliative care (1A).
Click to read original
6. Simulation! Shen Shre’s pharmaceutical protein pheasantol has been approved for listing by the United States FDA for treatment for transsexual breast cancer.
The brief new drug application (ANDA, i.e. the United States generic drug application) for injection of vixasol (protein combination) developed by Jiangsu Seng Shwe Medicines Inc. in cooperation with Sanders was approved by the United States Food and Drug Supervisory Authority (FDA) for the treatment of patients with transsexual breast cancer, the first of its kind approved by FDA.
